In the follow-up period and after 61 months treatment with tyrosine kinase inhibitors (TKIs), CML was undetectable in molecular tests, but the presence of serum M-protein, abnormal plasma cells in the bone marrow, and CRAB criteria was compatible with MM. The gene discussed is MYOM2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.